Genetic Manipulation of Equine Arteritis Virus Using Full-Length cDNA Clones: Separation of Overlapping Genes and Expression of a Foreign Epitope  by de Vries, Antoine A.F. et al.
C
P
Virology 270, 84–97 (2000)
doi:10.1006/viro.2000.0245, available online at http://www.idealibrary.com onGenetic Manipulation of Equine Arteritis Virus Using Full-Length cDNA Clones:
Separation of Overlapping Genes and Expression of a Foreign Epitope
Antoine A. F. de Vries,1 Amy L. Glaser,2 Martin J. B. Raamsman, Cornelis A. M. de Haan, Sonia Sarnataro,3
Gert-Jan Godeke, and Peter J. M. Rottier4
Virology Unit, Department of Infectious Diseases and Immunology, Veterinary Faculty, Utrecht University,
Yalelaan 1, 3584 CL Utrecht, The Netherlands
Received October 7, 1999; returned to author for revision December 1, 1999; accepted February 8, 2000
Equine arteritis virus (EAV) is an enveloped, positive-stranded RNA virus belonging to the family Arteriviridae of the order
Nidovirales. The unsegmented, infectious genome of EAV is 12,704 nt in length [exclusive of the poly(A) tail] and contains
eight overlapping genes that are expressed from a 39-coterminal nested set of seven leader-containing mRNAs. To
investigate the importance of the overlapping gene arrangement in the viral life-cycle and to facilitate the genetic manipu-
lation of the viral genome, a series of mutant full-length cDNA clones was constructed in which either EAV open reading
frames (ORFs) 4 and 5 or ORFs 5 and 6 or ORFs 4, 5, and 6 were separated by newly introduced AflII restriction endonuclease
cleavage sites. RNA transcribed from each of these plasmids was infectious, demonstrating that the overlapping gene
organization is not essential for EAV viability. Moreover, the recombinant viruses replicated with almost the same efficiency,
i.e., reached nearly the same infectious titers as the wildtype virus, and stably maintained the mutations that were introduced.
The AflII site engineered between ORFs 5 and 6 was subsequently used to generate a virus in which the ectodomain of the
ORF 6-encoded M protein was extended with nine amino acids derived from the extreme N-terminus of the homologous
protein of mouse hepatitis virus (MHV; family Coronaviridae, order Nidovirales). This nonapeptide contains a functional
O-glycosylation signal as well as an epitope recognized by an MHV-specific monoclonal antibody, both of which were
expressed by the recombinant virus. Although the hybrid virus had a clear growth disadvantage in comparison to the parental
virus, three serial passages did not result in the loss of the foreign genetic material. © 2000 Academic PressKey Words: equine arteritis virus; full-length cDNA clone; reverse transcription-polymerase chain reaction; overlapping
genes; chimeric M protein.INTRODUCTION
Equine arteritis virus (EAV), the etiological agent of
equine viral arteritis (EVA; Timoney and McCollum, 1993;
de Vries et al., 1996), is a spherical, enveloped, positive-
stranded RNA virus with a diameter of 50 to 70 nm. The
virus is the prototypic member of the monogeneric family
Arteriviridae, which further includes lactate dehydroge-
nase-elevating virus of mice, porcine reproductive and
respiratory syndrome virus (PRRSV), and simian hemor-
rhagic fever virus (SHFV). Although their physicochemi-
cal properties, genome sizes (12.7 to 15.7 kb), and virion
architecture would suggest otherwise, comparative se-
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84quence analyses of the polymerase polyproteins have
shown that arteriviruses are phylogenetically related to
corona- and toroviruses (for a review see de Vries et al.,
1997). The common ancestry of arteri-, corona-, and
toroviruses is further reflected by striking similarities in
genome organization, replication mechanism, gene ex-
pression strategy, and (site of) virus assembly (reviewed
in Snijder and Meulenberg, 1998) and has led to the
recent establishment of a new virus order, Nidovirales,
which includes both the Arteriviridae and the bigeneric
family Coronaviridae (Cavanagh, 1997).
EAV contains a putatively icosahedral core surrounded
by a lipid-containing envelope from which tiny spikes
protrude. The core particle is composed of the linear viral
genomic RNA and a single phosphorylated nucleocapsid
(N) protein (Hyllseth, 1973; Zeegers et al., 1976), while the
viral envelope contains five known structural proteins
(Hyllseth, 1973; de Vries et al., 1992; Snijder et al., 1999).
The unglycosylated membrane (M) protein of 16 kDa and
the 30- to 42-kDa large envelope glycoprotein (GL) are
major structural proteins and are present in virus parti-
cles as disulfide-linked heterodimers (de Vries et al.,
1995a). The 25-kDa small envelope glycoprotein (GS) and
a poorly characterized third glycoprotein of 26/38 kDa
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85GENETIC MANIPULATION OF THE EAV GENOMEare minor virion components. The recently discovered
8-kDa unglycosylated envelope (E) protein (Snijder et al.,
1999) is present in virus particles in intermediate
amounts.
The infectious genomic RNA of EAV has a length of
12,704 nt [exclusive of the poly(A) tail] and contains a 59
cap structure (Glaser et al., 1999). Eight genes have been
identified in the virus genome (den Boon et al., 1991;
Snijder et al., 1999). The 59 three-quarters of the viral
genome are occupied by two large open reading frames
(ORFs 1a and 1b), which are translated directly from the
genomic RNA (RNA 1; den Boon et al., 1991). The result-
ing ORF 1a and ORF lab proteins are cleaved by three
viral proteases into multiple subunits that are involved in
virus replication and/or transcription (van Dinten et al.,
999, and references herein). The genes for the other
iral proteins (ORFs 2a, 2b, and 3 through 7) are located
n the 39-terminal 3 kb of the EAV genome and are
xpressed from a 39-coterminal nested set of six leader-
ontaining subgenomic mRNAs (RNAs 2 through 7; de
ries et al., 1990). The leader sequence is derived from
he extreme 59 end of the viral genome and is fused to
he body segments of the subgenomic mRNAs at con-
erved hexanucleotide motifs [59 UCAAC(U/C)39] located
pstream of every transcription unit (de Vries et al., 1990;
den Boon et al., 1996). With the exception of RNA 7, the
subgenomic mRNAs of EAV are structurally polycistronic.
However, apart from RNA 2 (Snijder et al., 1999), they are
assumed to be functionally monocistronic, i.e., only the
most 59-proximal gene of each mRNA is translated. The
translation products of each of these genes are struc-
tural components of EAV particles with the possible ex-
ception of the ORF 3 protein (de Vries et al., 1992; Snijder
et al., 1999). The three most 39-proximal ORFs (ORFs 5, 6,
and 7) thus encode the major structural proteins GL, M,
nd N, respectively, whereas ORF 2a codes for the E
rotein (Snijder et al., 1999) and ORF 2b specifies the GS
protein (de Vries et al., 1992). Finally, the envelope gly-
coprotein of 26/38 kDa is encoded by ORF 4.
The recent construction of full-length cDNA clones of
EAV by van Dinten et al. (1997) and Glaser et al. (1999)
and of PRRSV by Meulenberg et al. (1998) has created
the possibility of specifically altering the genomes of
arteriviruses for fundamental studies, vaccine produc-
tion, and vector development. Manipulation of the ge-
nome of arteriviruses is, however, complicated by their
very condensed genomic structure. The genome of EAV
seems to possess only three short untranslated regions
that are located at the extreme 39 end (nt 12,646 to
12,704) and upstream of ORF 1a (nt 1 to 13 and 128 to
224; Kheyar et al., 1998) and that most likely contain
ssential replication and/or transcription signals. More-
ver, all EAV genes with the exception of ORF 7 overlap
t their 39 end with the 59 terminus of the next gene (den
oon et al., 1991; Snijder et al., 1999). The latter feature
ampers mutational analysis of especially the N- and
p
p-termini of the structural proteins of EAV and makes it
ifficult to insert heterologous genes into the viral ge-
ome.
In this article, we used the genomic EAV cDNA clones
btained by van Dinten et al. (1997) and Glaser et al.
1999) to evaluate the significance of the characteristic
verlapping gene arrangement of the virus. Our results
emonstrated that the separation of EAV ORFs 4 and 5
nd/or ORFs 5 and 6 by newly introduced AflII restriction
ndonuclease cleavage sites had only a limited effect on
irus replication. The mutant infectious cDNA clone in
hich the overlap between ORFs 5 and 6 had been
emoved was subsequently used to make a recombinant
irus in which the EAV M protein was N-terminally ex-
ended by a heterologous sequence expressing a foreign
pitope and a functional O-glycosylation signal.
RESULTS
eneration of EAV mutants with nonoverlapping
enes
To determine the importance of overlapping genes for
AV viability and to facilitate the genetic manipulation of
he viral genome, three mutant full-length cDNA clones
ere constructed in which AflII restriction sites were
ositioned in between EAV ORFs 4 and 5 and/or ORFs 5
nd 6 as described under Materials and Methods. For
his purpose, we used the infectious cDNA clone
BRNX1.38 (Glaser et al., 1999) and/or pEAV030 (van
inten et al., 1997). The resulting constructs were des-
gnated pBRNX1.38-5/6, pEAV030-5/6, pEAV030-BglIIKO-
/5, and pEAV030-BglIIKO-456 (Fig. 1). In vitro transcripts
erived from wildtype and mutant genomic cDNA clones
ere introduced into BHK-21 cells by electroporation.
uring the second day after transfection, the develop-
ent of a clear cytopathic effect (CPE) was observed in
ells transfected with EAV RNA but not in mock-treated
ells. The infection had progressed slightly further in the
ells that had received either of the wildtype transcripts
han in cells transfected with the mutant viral genomes.
he culture media were harvested at the moment of
aximum CPE and used to infect fresh monolayers of
HK-21 cells. As soon as these cells displayed a pro-
ounced CPE, the culture supernatants were collected
nd the infectivity in each sample was determined in a
CID50 assay using RK-13 cells as the indicator cells. The
virus titers ranged from 67 3 107 TCID50 units per milli-
liter for the pBRNX1.38-5/6 virus to 62 3 108 TCID50 units
er milliliter for the pEAV30-BglIIKO-4/5 and pEAV030-
glIIKO-456 viruses. As the titers of the viral mutants
pproached those of wildtype EAV, we concluded that
he removal of the overlaps between ORFs 4, 5, and 6 did
ot significantly impair virus replication or infectivity.
To study their genetic stability, the mutant viruses were
assaged two more times in BHK-21 cells. Total cyto-
lasmic RNA was then extracted from these cells and
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86 DE VRIES ET AL.virus-specific sequences were amplified by reverse tran-
scription (RT)-polymerase chain reaction (PCR) using a
sense primer located in ORF 4 [oligonucleotide 836 (1)]
and an antisense primer binding to the M gene [oligo-
nucleotide 766 (2); see Table 1 and Fig. 1]. For compar-
FIG. 1. Structure of wildtype and mutant full-length EAV cDNA clone
9 nontranslated region is displayed. Diamonds symbolize the DNA com
iral subgenomic mRNA synthesis. The mutations introduced to separa
re indicated. In each case, the second line shows the nucleotide s
ucleotides shown in lowercase; e.g., pBRNX1.38-5/6 (5/6) contains a 1
ucleotide sequence of the parental cDNA clone is given but only at pos
nd fourth lines denote amino acid residues. The MHV-specific amino
ntroduced during cloning, the glutamic acid at position 9 of the chim
equence of the hybrid virus vector (M9F) is compared to that of pBRN
ndicated below the map of the wildtype EAV cDNA clone.ison, the same primer set was also used for a PCR
analysis of the infectious cDNA clones specifying thedifferent viruses. To determine whether the mutant vi-
ruses still contained the engineered restriction endonu-
clease cleavage sites, the resulting PCR products were
analyzed by agarose gel electrophoresis before and after
AflII digestion. In each case, the band patterns obtained
ach plasmid, only the region covering EAV ORFs 4 through 7 and the
nt of the UCAAC(U/C) boxes that regulate leader-to-body fusion during
s 4 and 5 and ORFs 5 and 6 and to create a hybrid EAV/MHV M gene
e of relevant parts of the mutant virus vector with newly introduced
sertion compared to the wildtype cDNA construct. In the first line, the
that have been altered during PCR mutagenesis. The letters in the third
are printed in lowercase. As a result of an unintended G 3 A change
rotein was substituted for a lysine residue. Note that the nucleotide
/6 and that the positions of oligonucleotides 836 (1) and 766 (2) ares. For e
pleme
te ORF
equenc
7-nt in
itions
acids
eric pwith the RNA samples (Fig. 2, middle) were identical to
those of the DNA templates (Fig. 2, top) and the PCR
oprimer
999).
87GENETIC MANIPULATION OF THE EAV GENOMEfragments were always of the correct size. Altogether our
data indicate that the spacing between genes is not of
critical importance to the virus and that the additional 17
to 41 nt introduced during the separation of ORFs 4 and
5 and/or ORFs 5 and 6 are stably maintained within the
EAV genome.
To test whether the newly introduced sequences af-
fected viral transcription, we performed another RT-PCR
using a leader-specific upstream primer [oligonucleotide
A18 (1)] and a downstream primer located in the 59 end
of ORF 7 [oligonucleotide 063 (2)] or in the middle of
ORF 6 [oligonucleotide 32 (2); see Table 1] on RNA
extracted from cells infected with pBRNX1.38 virus or
with pBRNX1.38-5/6 virus that had been passaged twice
before. The resulting PCR products were left undigested
or incubated with AflII and separated in an agarose gel.
As is shown in Fig. 3, multiple DNA fragments corre-
sponding to the different virus-specific mRNAs were re-
solved for both viruses. Interestingly, two amplification
products were obtained for EAV RNA 5 (Fig. 3) although
only one leader-to-body fusion site was previously iden-
tified for this mRNA species by den Boon et al. (1996). No
clear differences in the band patterns were observed
T
Oligodeox
Namea Sequenceb
A07 (1) CCTCGAGGGCCTACGGCAGCAAAGTCA
A16 (2) AGCAACTGGGACCGCGTAGG
A18 (1) GCTCGAAGTGTGTATGGTGC
032 (2) AATGGACCGAAAGACG
063 (2) ACGTGATCGTCTTGAC
152 (2) CCGCGATCCGTCAGC
337 (2) CTTCAACATGACGCCACACAGGAG
434 (2) CAGTAGGTCATTGTAGCTTG
461 (1) CGGGATCCGCTTACTTCTCATACTACACC
578 (2) CGGGATCCAACACAACTATGCCGAATTCAC
647 (2) CGTCACCACAAAATGAATCTATAGCGCCCATGGCCTT-
AAGGCTCCCAcACCTCAGCTGCCCC
688 (1) GCtATAGATTCATTTTGTGGTGACG
689 (1) TCTATGGCATTTACAGCG
766 (2) CCAGATGCTACATACCTAGTA
787 (1) GAACTTAAGCAACATGCTGTCCATGATTGTATTGCTA-
TTCTTGCT
788 (2) CAGCATGTTGCTTAAGTTCAcAGATAACAgCGTTGAG-
CCCAACGT
789 (1) GTAGTCATACCAACTCAACTA
792 (1) CAAGCACCAGAGCCCGGcGCCATAGATTCATTTTGTG
793 (2) GGGCTCTGGTGCTTGTGTAGTAGAACTCATGGCCTTA-
aGGCTC
836 (1) AAACTGCAGCCGTTTGGGTATCA
a Positive-sense primers are marked (1); negative-sense primers ar
b Extragenomic nucleotides are singly underlined, point mutations a
c The positions of the virus-specific sequences encoded by individual
et al. (1991) including the 59-terminal 17 nt resolved by Glaser et al. (1between the wildtype and the mutant virus, suggesting
that the separation of ORFs 5 and 6 did not detectably
w
tinfluence the relative and absolute transcription levels of
the viral subgenomic mRNAs. As expected, the PCR
fragments corresponding to the subgenomic mRNAs of
the mutant virus all contained an AflII restriction enzyme
recognition site, with the exception of RNA 7. It thus
appeared that in the pBRNX1.38-5/6 virus leader-to-body
fusion occurs at the same 59 UCAACC 39 box as in the
wildtype virus. The lengths of the DNA fragments ob-
tained for the mutant virus are consistent with this notion.
Analysis of the virus-specific transcripts by denaturing
agarose gel electrophoresis followed by in situ hybrid-
ization using oligonucleotide 337 (2) confirmed that viral
transcription proceeds normally for the mutant virus (de
Vries et al., in preparation). However, the mutant virus
appeared to be somewhat delayed in its growth kinetics,
resulting in a slower accumulation of viral subgenomic
mRNAs and virus-specific proteins (see, e.g., Fig. 6).
Analysis of RNA 5 leader-to-body fusion sites
As mentioned above, RT-PCR amplification of the in-
tracellular EAV RNAs using primers A18 (1) and 063 (2)
r A18 (1) and 032 (2) yielded a doublet for RNA 5,
cleotides
Positionc Use
1,853–11,872 SOE–PCR to generate hybrid EAV/MHV M gene
1,393–11,412 cDNA synthesis
1–20 Analytical PCR
2,168–12,182 Analytical RT-PCR
2,318–12,333 Analytical RT-PCR
1,250–11,264 Analytical PCR; nucleotide sequence analysis
2,658–12,681 Hybridization analysis
2,377–12,396 SOE–PCR to separate ORFs 5 and 6; SOE–PCR
to generate hybrid EAV/MHV M gene
1,197–11,217 SOE–PCR to separate ORFs 5 and 6
1,486–11,511 SOE–PCR to separate ORFs 4 and 5
1,887–11,931 SOE–PCR to separate ORFs 5 and 6
1,907–11,931 SOE–PCR to separate ORFs 5 and 6
1,609–11,626 SOE–PCR to generate hybrid EAV/MHV M gene
1,990–12,010 Analytical RT-PCR
1,157–11,177 SOE–PCR to separate ORFs 4 and 5
1,131–11,168 SOE–PCR to separate ORFs 4 and 5
0,646–10,666 SOE–PCR to separate ORFs 4 and 5
1,904–11,925 SOE–PCR to generate hybrid EAV/MHV M gene
1,905–11,912 SOE–PCR to generate hybrid EAV/MHV M gene
0,988–11,007 Analytical PCR
olized by (2).
n in lowercase, and MHV-specific sequences are doubly underlined.
s are based on the genomic EAV sequence as determined by den BoonABLE 1
yribonu
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88 DE VRIES ET AL.hypothesis, total cytoplasmic RNA extracted from
pBRNX1.38-5/6 virus-infected BHK-21 cells was reverse-
transcribed with the ORF 5-specific oligonucleotide A16
FIG. 2. RT-PCR analysis of ORF 5 and its flanking regions using total
cytoplasmic RNA purified from mock-infected (neg) BHK-21 cells or
from BHK-21 cells infected with the third passage of viruses encoded
by pBRNX1.38 (clo), pBRNX1.38-5/6 (5/6), pEAV030-BglIIKO-4/5 (4/5),
pEAV030-BglIIKO-456 (456), or pBRNX1.38-5/6-M9F (hyb) (middle). cDNA
ynthesis was primed with oligonucleotide 766 (2); for PCR amplifica-
ion primers 836 (1) and 766 (2) were used (see Table 1 and Fig. 1).
he anticipated sizes of the RT-PCR fragments and their AflII digestion
roducts are given in the table below the gel pictures (bottom). For
omparison, the plasmids specifying each of the viruses were also
ubjected to PCR analyses using the same primer pair (top). In the
atter experiment, a PCR performed without template DNA served as a
egative control (neg). M1 and M2 represent HinfI-digested pGEX-2T
NA and PstI-digested bacteriophage l DNA, respectively.(2) (Table 1) and the resulting cDNA was amplified by
PCR using primers A18 (1) and 152 (2) (see Table 1 and
e
sFig. 4). This yielded a major fragment of 6440 bp and a
minor product of 6330 bp as well as small amounts of
some higher molecular weight species (data not shown).
The two small products were purified from gel, reampli-
fied with oligonucleotides A18 (1) and 152 (2), and
cloned into the pGEM-T Easy. Recombinant plasmids
representative of both PCR fragments were then sub-
jected to nucleotide sequence analysis using oligonucle-
otide 152 (2) as a primer. As is shown in Fig. 4B, the
sequence of the longer PCR fragment corroborated the
previous result of den Boon et al. (1996) that the 59
UCAACU 39 box at position 11,028 of the EAV genome is
a functional leader-to-body fusion site. The sequence of
the shorter PCR fragment, however, demonstrated that
there is a second functional leader-to-body fusion site (59
UCAACG 39) located immediately upstream of ORF 5 at
genomic position 11,140. Furthermore, the relative
amounts of the initial PCR products indicated that the
downstream 59 UCAACG 39 is less effective in directing
discontinuous mRNA synthesis than the upstream inter-
nal transcription signal (Fig. 4B).
Construction of chimeric EAV/mouse hepatitis virus
(MHV) M proteins
We next wanted to explore the use of our mutant
infectious cDNA clones for the further manipulation of
the virus. To investigate whether heterologous se-
quences could be expressed at the surface of EAV par-
ticles, we constructed two EAV/MHV M hybrids (denom-
inated M4A and M9F) in which the N-terminal 5 or 10
mino acids of the MHV M protein were fused to the EAV
-coding sequence immediately upstream of its Gly res-
due at position 2 (Fig. 5, third panel). The reasons to
ake these particular hybrid molecules were threefold:
i) the M proteins of arteri- and coronaviruses are as-
umed to be functional homologues and to have the
ame triple-spanning transmembrane topology with a
mall (10 to 40 aa) N-terminal ectodomain and a large (80
o 130 aa) C-terminal endodomain (de Vries et al., 1992);
ii) the N-terminus of the MHV M protein is recognized by
onoclonal antibody (MAb) J.1.3 (de Haan et al., 1998a;
leming et al., 1989) and could serve as a tag to localize
he EAV M protein in virus-infected cells and virus parti-
les; and (iii) the N-terminus of the MHV M protein
ontains a functional O-glycosylation signal (de Haan et
l., 1998b). If the chimeric EAV/MHV M molecules would
lso become O-glycosylated, this feature could be ex-
loited to follow their intracellular transport by analyzing
he composition of the sugar chains as has been de-
cribed previously for the MHV M protein (see Krijnse
ocker et al., 1992, and references therein).
Before insertion of the hybrid EAV/MHV M genes into
n infectious EAV cDNA clone, we first tested the prop-
rties of the encoded proteins after independent expres-
ion in the MVA-T7 system (Sutter et al., 1995). To this
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89GENETIC MANIPULATION OF THE EAV GENOMEend, MVA-T7-infected OST-7.1 cells were transfected with
plasmids encoding the wildtype EAV M protein (de Vries
et al., 1992), both EAV/MHV M chimeras, and an MHV M
utant carrying a C-terminal endoplasmic reticulum (ER)
etrieval signal (designated MKK; de Haan et al., 1998b;
Fig. 5, fourth panel). After metabolic labeling of the cells
for 1 h with [35S]Met 1 [35S]Cys, cell lysates were pre-
pared and incubated with antibodies specific for the
N-terminus of the MHV M protein (MAb J.1.3) or the
C-terminus of the EAV M protein. As expected, the EAV
M-specific antipeptide serum recognized the wildtype
EAV M protein and both EAV/MHV hybrids but not the
MHV MKK protein (Fig. 5, first panel). In contrast, MAb J.1.3
mmunoprecipitated the MHV MKK protein as well as the
wo EAV/MHV chimeras but not the EAV M protein (Fig. 5,
econd panel). The recognition of M4A by MAb J.1.3 was
surprising since it contains only a cluster of five MHV-
specific amino acids (MSSTT). It is of note, however, that
MAb J.1.3 bound to the M4A protein much less efficiently
than to the M9F hybrid. The apparent molecular weight of
the four polypeptides was consistent with their predicted
size; i.e., the EAV M protein (162 residues) migrated the
fastest while the MHV MKK mutant (228 aa) moved slow-
st. Moreover, the electrophoretic mobility of M4A (166
residues) was slightly lower than that of the wildtype EAV
M protein but clearly larger than that of M9F (171 aa). In
each case only a single protein species was observed by
SDS–polyacrylamide gel electrophoresis (SDS–PAGE),
indicating that none of the polypeptides became O-gly-
cosylated, which is consistent with their localization in
the ER (de Haan et al., 1998b, and unpublished data). To
FIG. 3. RT-PCR analysis of the virus-specific intracellular RNAs usi
passage of viruses derived from pBRNX1.38 (clo) and pBRNX1.38-5/6 (
oligonucleotide 032 (2); for PCR amplification the RT primers were u
products were analyzed directly or after treatment with AflII as indicate
7 are marked by refracted lines. The open triangles show the position
derived from pBRNX1.38-5/6 virus-infected BHK-21 cells. The amplificat
to emphasize that it does not cover the area where the AflII site was in
to RNA 7 is lacking from the right panel of the figure because oligonuc
M1 and M2 represent EcoRI- and HindIII-digested bacteriophage l DNassess whether the EAV/MHV M hybrids expressed a
functional O-glycosylation site, in a parallel experiment bthe cells were incubated in the presence of brefeldin A,
which is known to cause the redistribution of enzymes
involved in O-glycosylation to the ER (de Haan et al.,
1998b). Under these conditions, a part of the MHVKK and
M9F molecules showed the typical increase in apparent
molecular weight associated with O-glycosylation (Fig. 5,
top two panels). M4A and the wildtype EAV M protein did
not acquire sugar modifications as evidenced by the fact
that their electrophoretic mobility remained unaltered.
Since M9F was efficiently recognized by MAb J.1.3 and
contained a functional O-glycosylation site, we replaced
the EAV M gene in full-length EAV cDNA clone
pBRNX1.38-5/6 (Fig. 1) with that of the hybrid protein,
yielding plasmid pBRNX1.38-5/6-M9F. BHK-21 cells were
transfected with run-off transcripts derived from this con-
struct. The clear development of cytopathic changes in
the cell monolayers indicated that the M9F virus was
viable. To investigate the genetic stability of the recom-
binant virus, the culture medium of the transfected cells
was passaged three times. Total cytoplasmic RNA was
extracted from cells infected with third-passage virus
and the genome segment containing the MHV-specific
sequences was amplified by RT-PCR using primers 836
(1) and 766 (2). A fraction of the resulting PCR product
was cloned into pNoTA/T7TM; the rest was analyzed by
garose gel electrophoresis following restriction enzyme
nalysis. As is shown in Fig. 2, a PCR fragment of the
xpected size and containing an internal AflII site was
ynthesized, which demonstrated that no gross changes
ad occurred in ORF 5 or the 59 part of the M9F gene. To
exclude the possibility that point mutations had been
9F
l cytoplasmic RNA purified from BHK-21 cells infected with the third
NA synthesis was primed either with oligonucleotide 063 (2) or with
combination with oligonucleotide A18 (1) (see Table 1). The RT-PCR
positions of the (59) DNA fragments corresponding to RNAs 2 through
9 DNA fragments obtained after AflII digestion of the RT-PCR products
duct of RNA 7 in the left panel is indicated by a double-headed arrow
n pBRNX1.38-5/6. Please note that an RT-PCR fragment corresponding
032 (2) is located upstream of the RNA 7 leader-to-body junction site.
HinfI-digested pGEX-2T DNA, respectively.ng tota
5/6). cD
sed in
d. The
of the 3
ion pro
serted iintroduced in the M gene during passage of the recom-
inant virus that were not detected by gel electrophore-
(
A
t
i
5
N
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90 DE VRIES ET AL.sis and restriction enzyme analysis, three clones were
sequenced. None of them contained any unintended
substitutions in the genomic region enclosed by oligo-
FIG. 4. (A) Nucleotide sequence of the 59 part of EAV RNA 5 (den Boo
5.1) is underlined as is the newly discovered hexanucleotide transcrip
16(2) are highlighted. (B) Structure of the two EAV RNA 5 species. T
riangles at the left of both drawings represent the 59 cap structure; th
ndicated in the leader sequence, the EAV RNA 5.1 has a length of 188
is represented by a gray rectangle to emphasize that it is actively tra
genes are depicted by white boxes. The binding sites for oligonucleo
ach drawing. The deduced nucleotide sequence of relevant parts (nu
he figure.nucleotides A07 (1) and 766 (2) (data not shown). Al-
though point mutations elsewhere in the viral genomecan of course not be excluded, the results indicate that
the pBRNX1.38-5/6-M9F virus is stable (data not shown).
In EAV particles, M is covalently linked to the GL
., 1996). The previously identified EAV RNA 5 leader-to-body fusion site
gnal (5.2). The binding sites for oligonucleotides A18 (1), 152(2), and
er part shows a schematic diagram of both mRNAs. The large black
bols (A)n at the 39 end of the RNAs correspond to the poly(A) tail. As
ithout a poly(A) tract, whereas EAV RNA 5.2 is 1771 nt long. EAV ORF
d from both EAV RNA 5 species while the translationally silent M and
8 (1), 152(2), and A16(2) are indicated by small black triangles below
1, 2, and 3) of both EAV RNA 5 species is shown in the lower part ofn et al
tion si
he upp
e sym
3 nt w
nslate
tides A1protein. The association between these two proteins
occurs in a pre-Golgi compartment and is thought to be
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91GENETIC MANIPULATION OF THE EAV GENOMEessential for their function. Whereas the GL protein is
quantitatively recruited into GL/M complexes, part of the
ntracellular M molecules persist as monomers and dis-
lfide-bonded homodimers (de Vries et al., 1995a). To
tudy the formation of covalently linked heterodimers of
he GL protein and M
9F, we infected BHK-21 cells with the
BRNX1.38-5/6-M9F virus, wildtype EAV, or the
pBRNX1.38-5/6 virus. At 8 to 16 h postinfection (p.i.), the
cells were labeled for 30 min with [35S]Met 1 [35S]Cys
and total lysates of cells and media were prepared.
Alternatively, the pulse-labeling was followed by a 2-h
chase or the cells were continuously labeled for 4 h after
FIG. 5. Independent expression of the wildtype EAV M protein (MWT),
EAV/MHV M chimeras containing four (M4A) or nine (M9F) MHV-specific
amino acids, and an MHV M mutant with an ER retrieval signal (MKK).
VA-T7-infected and plasmid DNA-transfected OST-7.1 cells were la-
eled with [35S]Met 1 [35S]Cys for 60 min at 5 h p.i. in the presence (1)
r in the absence (2) of brefeldin A (BFA). Cell lysates were then
repared and incubated with a rabbit antiserum specific for the C-
erminus of the EAV M protein (aEAV MCOOH) or with mouse MAb J.1.3
directed against the N-terminus of the MHV M protein (aMHV MNH2).
The results of the immunoprecipitation analyses are shown in the top
two panels. The positions and sizes (in kDa) of 14C-labeled marker
roteins analyzed in the same gel are indicated. In the bottom two
anels, the amino acid sequences of relevant parts of each protein are
isplayed. EAV-specific residues are shown in black, MHV-specific
mino acids are outlined, and the ER retrieval signal is underlined.which the cells and media were processed separately.
Aliquots of each protein sample were incubated with tantibodies specific for the EAV M or GL protein and the
mmune complexes were analyzed by SDS–PAGE. As is
hown in the left panel of Fig. 6A, the EAV M protein
xtracted from pBRNX1.38-5/6-M9F virus-infected cells
was 62 kDa larger than that produced by cells infected
with either control virus. Although its detection after the
chase was hampered by the variable processing of its
N-glycan and by the relatively short exposure time used
to generate Fig. 6A, small amounts of the EAV GL protein
ere always coprecipitated with M9F, indicating that the
MHV-specific epitope did not block GL/M heterodimer-
zation. Using the M-specific antiserum, hardly any
-glycosylated M9F could be detected in virus-infected
FIG. 6. Immunoprecipitation analysis of the M and GL proteins
produced by BHK-21 cells infected with pBRNX1.38 virus (clo),
pBRNX1.38-5/6 virus (5/6), or pBRNX1.38-5/6-M9F virus (hyb). Mock- or
irus-infected cells were pulse-labeled for 30 min with [35S]Met 1
[35S]Cys at 8 h (clo), 12 h (mock and 5/6), or 16 h (hyb) p.i. and chased
or 2 h (left). Total lysates of cells and media were then prepared and
ixed with a rabbit antiserum specific for the C-terminus of the EAV M
rotein (aEAV MCOOH; A) or with murine MAb 93B directed against the
ectodomain of the EAV GL protein (aEAV GL
ECTO; B). Alternatively, the
cells were continuously labeled for 4 h, and the culture supernatants
(containing extracellular virions) were harvested, mixed with deter-
gents, and incubated with the same antibodies (right). The positions of
the wildtype N, M, and GL proteins of EAV are shown at the right as are
he positions of the unglycosylated EAV/MHV M hybrid (M9) and its
-glycosylated counterpart (M91). The positions and sizes (in kDa) of
14C-labeled marker proteins analyzed in the same gel are indicated at
he left.
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92 DE VRIES ET AL.cells after the chase (Fig. 6A). However, incubation of the
same lysate with the GL-specific MAb 93B resulted in the
immunoprecipitation of two glycoforms of the M9F protein
n approximately equal amounts (Fig. 6B). These results
emonstrate that the vast majority of M molecules in
BRNX1.38-5/6-M9F virus-infected cells never become
-glycosylated and that the GL/M
9F heterodimers acquire
-linked glycans after leaving the ER. In virions, all the
9F molecules were O-glycosylated and disulfide-linked
to the GL protein (compare the right panels of Figs. 6A
and 6B). The presence of minor amounts of N protein in
each of the immunoprecipitates most likely resulted from
its direct binding to the immunosorbent and/or its aggre-
gation during cell lysis and/or antibody incubation (de
Vries et al., 1995a). When tested with the same protein
extracts, the MHV M-specific MAb J.1.3 recognized the
hybrid EAV/MHV M molecules and complexes thereof
but not the wildtype M protein of EAV (data not shown).
DISCUSSION
In contrast to coronaviruses, which typically have the
leader-to-body fusion sites for the subgenomic mRNAs
located in between viral ORFs, the genes of arteriviruses
are usually overlapping and the leader-to-body junction
sequences are invariably located within coding se-
quences. To investigate the importance of the overlap-
ping gene organization for arterivirus viability, we con-
structed EAV mutants that had the overlap between ORFs
4 and 5 and/or ORFs 5 and 6 removed. It appeared that
each of these viral mutants was viable, which demon-
strates that overlapping genes are not an obligatory
requirement for arteriviruses. The recent observation
that in PRRSV strain VR-2332 (Nelsen et al., 1999) and in
the LVR 42-0/M6941 strain of SHFV (Smith et al., 1997),
the homologues of EAV ORFs 4 and 5 are separated by
10 and 2 nt, respectively, is consistent with this notion.
Why then do arteriviruses possess such compact ge-
nomes containing only three very small nontranslated
regions? Would there be packaging constraints imposed
by the putatively icosahedral nucleocapsid structure of
EAV? Our results argue against this possibility since the
genomes of the mutant viruses are only a fraction (17 to
41 nt) longer than that of wildtype EAV, provided that their
poly(A) tails are of equal size. Moreover, the genome
length of arteriviruses varies from less than 13 kb for EAV
to almost 16 kb for SHFV while their nucleocapsid pro-
teins are very similar in size, i.e., 110 amino acids for EAV
and 111 amino acids for SHFV (reviewed by Snijder and
Meulenberg, 1998). We therefore propose that the over-
lapping gene arrangement constitutes a means by which
arteriviruses preserve the genetic integrity of vital parts
of their genomes, providing strong selection against nu-
cleotide changes that would affect the termini of the
encoded proteins. The very efficient genome organiza-
tion and icosahedral virion architecture of arterivirusesmake them more economical but less flexible than coro-
naviruses, which possess a fundamental set of five non-
overlapping genes and have a helical capsid structure.
As a result, coronaviruses can easily take up foreign
genetic information without disrupting their basic ge-
nome structure or encountering packaging constraints.
This allows them to quickly adapt to environmental
changes and to increase their fitness. There are indeed
many examples of recombination events in coronavi-
ruses that have led to the acquisition of heterologous
sequences (reviewed by Lai, 1996). Accordingly, each
coronavirus contains a unique set of supplementary
ORFs that are interspersed between the essential genes.
In contrast, there is no evidence for the recent incorpo-
ration of foreign genes into the genomes of arteriviruses.
This may explain why the genetic composition and gene
order of all arteriviruses are identical [except for a dupli-
cation of three genes in SHFV (Godeny et al., 1998)]. It
thus seems that arteri- and coronaviruses are represen-
tatives of two different lifestyles within the same virus
order. Whereas the evolutionary success of arteriviruses
is based on a small (13 to 16 kb) and rather rigid genome,
coronaviruses rely on a plastic but very large (27 to 31
kb) genome for their survival. This exacts a high standard
of reliability to the coronaviral replicase.
The maximum titers obtained for the virus mutants in
which ORFs 4 and 5 and/or ORFs 5 and 6 had been
separated were only slightly lower than those obtained
for the parental viruses, indicating that small changes in
the spacing between EAV genes have only a limited
effect on virus yields. Since a detailed biological charac-
terization of the mutant viruses was beyond the scope of
this paper, the precise reason for the drop in virus titers
resulting from the separation of the ORFs is unknown. A
possible effect on virus assembly and/or entry seems
unlikely in view of the minor contribution of the inserted
sequences to the total genome size unless the genomic
packaging signal was affected by the mutations that
were introduced. Furthermore, metabolic labeling exper-
iments performed at different times p.i. using BHK-21
cells that were infected at a high multiplicity of infection
with pBRNX1.38 or pBRNX1.38-5/6 virus revealed no
gross changes in the relative expression levels of the GS,
GL, M, and N proteins even though the context of the
translation initiation codon of ORF 6 was clearly altered
in the latter virus. From the same experiment, we con-
cluded that in pBRNX1.36-5/6 virus-infected cells, viral
protein synthesis was initiated more slowly than in cells
infected with the progenitor virus (data not shown). It
thus seems that the 17-nt insertion had a direct effect on
genome replication and/or stability. A possible delay in
viral growth kinetics would also be consistent with the
slow spread and the reduced cytotoxicity of the mutant
virus. To substantiate this claim and to learn more about
the pEAV030-5/6, pEAV030-BglIIKO-4/5, and pEAV030-
BglIIKO-456 viruses, additional experiments are required,
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93GENETIC MANIPULATION OF THE EAV GENOMEincluding the determination of one-step growth curves
for each of the viral mutants as well as the parental
viruses.
The availability of infectious EAV cDNA clones in
which ORFs 4 and 5 and/or ORFs 5 and 6 are separated
now allows us to easily perform mutational analyses of
the C-terminus of the ORF 4 protein, the N-terminus of
the M protein, and the entire GL protein. As an initial test
o determine whether further manipulation of the EAV
enome would be possible, we constructed a recombi-
ant virus containing a chimeric EAV/MHV M protein that
xpresses a functional O-glycosylation site and an
pitope recognized by an MHV M-specific MAb. Albeit
learly infectious, the hybrid virus had a serious growth
isadvantage in comparison to the pBRNX1.36-5/6 virus
Fig. 6) and reached a maximum titer of only some 2 3
06 TCID50 units per milliliter (data not shown). It is
nclear whether the low titer of the pBRNX1.36-5/6-M9F
virus merely reflects a decrease in the virion production
or is also due to a reduction of the specific infectivity
(e.g., as a result of inefficient cell entry and/or low virus
stability). However, the EAV/MHV M chimera normally
formed covalently linked heterodimers with the EAV GL
protein, even though the MHV M-specific nonapeptide
was located very close to the luminal cysteine residue of
the EAV M protein known to be involved in intermolecular
disulfide bond formation (de Vries et al., 1995a). More-
over, complex formation between the M9F protein and GL
appeared to occur prior to and did not interfere with
O-linked glycosylation, consistent with the notion that
oligomerization occurs in the ER while the addition of
O-linked sugars takes place in a post-ER compartment
(Ro¨ttger et al., 1998).
Although the pBRNX1.38-5/6-M9F virus is probably se-
verely attenuated compared to the parental virus, our
results indicate that the N-terminus of the EAV M protein
can accommodate heterologous peptides without abol-
ishing viral infectivity. The M protein may therefore be
used as a carrier for the expression of epitopes from
other equine pathogens in the context of a (mild) EAV
infection. If such foreign epitopes would be properly
presented to the immune system of the host, it might
form the basis for the development of a multivalent
(marker) vaccine that could simultaneously provide pro-
tection against different infectious diseases of the horse.
An experimental infection of a horse with the pBRNX1.38-
5/6-M9F virus could provide further information about the
feasibility of this approach. As MAb J.1.3 has been shown
to block MHV infectivity in the presence of complement
(Fleming et al., 1989), it would also be of interest to test
whether the pBRNX1.38-5/6-M9F virus can be neutralized
by this antibody either in the absence or in the presence
of complement.
An unexpected outcome of the analysis by RT-PCR of
the virus-specific mRNAs was the discovery of a new
functional leader-to-body fusion site immediately up-
V
nstream of the ORF 5 start codon at position 11,140 within
the EAV genome. This observation suggests that two
different mRNAs are used to express EAV ORF 5 or that
the longest of both EAV RNA 5 species (designated RNA
5.1) directs the synthesis of a yet unidentified protein.
The latter possibility is, however, unlikely since the
unique part of RNA 5.1 (compared to the newly identified
RNA 5.2) does not contain an AUG codon in a favorable
context for translation initiation to occur. Furthermore,
our experiments showed that RNA 5.2 is expressed in
much lower amounts than RNA 5.1, probably as a result
of the presence of a 39 G residue in the hexanucleotide
consensus sequence regulating the synthesis of the
shortest RNA 5 species. It thus seems that RNA 5.2 does
not significantly contribute to the synthesis of the EAV GL
protein. The low abundance of RNA 5.2 and the fact that
den Boon et al. (1996) amplified the RNA 5-specific cDNA
with an antisense primer located upstream of the RNA
5.2 leader-to-body fusion site also explain why the
shorter transcript was missed by these authors. The use
of alternative leader-to-body junction sequences for the
synthesis of specific arteriviral mRNAs is not without
precedent. Recently, Nelsen et al. (1999) reported that
two RNAs were produced to express ORFs 4, 5, and 7 of
the VR-2332 strain of PRRSV, whereas in EAV-infected
cells multiple RNA 3 species were already detected
previously by den Boon et al. (1996).
MATERIALS AND METHODS
Antisera, cells, and viruses
Cells were cultured in a humidified air–5% CO2 atmo-
phere. EAV infections and RNA transfections were per-
ormed with BHK-21 (C-13) cells (American Type Culture
ollection) maintained in Glasgow minimum essential
edium (GMEM; Gibco BRL Life Technologies) contain-
ng 10% fetal bovine serum (FBS), 100 U of penicillin per
illiliter, and 100 mg of streptomycin per milliliter
(GMEM–10% FBS). TCID50 assays of EAV were carried
ut essentially as reported by Hyllseth (1969) using RK-13
ells grown in Dulbecco’s modified Eagle’s medium
DMEM; Gibco BRL Life Technologies) with 10% FBS and
he aforementioned antibiotics (DMEM–10% FBS).
Modified vaccinia virus Ankara expressing the bacte-
iophage T7 DNA-dependent RNA polymerase (MVA-T7;
utter et al., 1995) was propagated and titrated in
hicken embryonic fibroblasts maintained in GMEM–
0% FBS. Transient expression studies were carried out
n OST-7.1 cells (Elroy-Stein and Moss, 1990) cultured in
MEM–10% FBS.
The production and characterization of a rabbit anti-
erum directed against the C-terminal 18 amino acids of
he EAV M protein have been documented previously (de
ries et al., 1992). The murine MAb 93B, which recog-
izes the EAV GL protein, was generated by Glaser et al.
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94 DE VRIES ET AL.(1995). The MHV M-specific MAb J.1.3 was produced by
Fleming et al. (1989).
RNA extraction and gel electrophoresis
Total cytoplasmic RNA was extracted from cultured
cells according to Spaan et al. (1981). For hybridization
analysis RNAs were separated in 2.2 M formaldehyde–
1.5 to 1.75% agarose gels and probed in situ with
[g-32P]ATP-labeled oligodeoxyribonucleotides at 5°C be-
low their theoretical dissociation temperature (T d) as
etermined by the formula T d 5 4 3 (G 1 C) 1 2 3 (A 1
T) (de Vries et al., 1990).
cDNA synthesis, PCR amplification, and DNA
sequencing
Total cytoplasmic RNA obtained from 2 to 4 cm2 of
AV-infected BHK-21 cells was mixed with 10 to 50 pmol
f virus-specific primer in a total volume of 11.5 ml, incu-
ated for 10 min at 65°C, and immediately cooled on ice.
ext, 4 ml of 250 mM Tris–HCl (pH 8.3 at 25°C), 200 mM
Cl, 25 mM MgCl2, 2.5% Tween 20, 2 ml of 100 mM DTT,
.8 ml of a 25 mM concentration of each dNTP, 0.7 ml of
RNAguard (33.4 U/ml; Amersham Pharmacia Biotech),
nd 1 ml of Expand reverse transcriptase (50 U/ml; Boeh-
ringer Mannheim) were added and the sample was in-
cubated for 1 h at 42°C. After termination of the reaction
on ice, the cDNA solution was temporarily stored at
220°C.
For site-directed mutagenesis and analytical pur-
poses, we routinely utilized Thermus aquaticus DNA
polymerase (Gibco BRL Life Technologies). A standard
PCR mixture of 50 ml contained 1 ng of plasmid DNA or
ml of cDNA, 20 mM Tris–HCl (pH 8.4), 50 mM KCl, 2 mM
MgCl2, a 200 to 400 mM concentration of each dNTP, 10
to 25 pmol of both the sense and the antisense primers,
and 2 to 3 U of enzyme. The samples were prepared on
ice, overlaid with 25 ml of mineral oil, and placed in a
preheated thermocycler (Perkin–Elmer) at 94°C for 2 min.
The target sequences were amplified in 25 to 30 cycles.
Each round of amplification consisted of a denaturation
step at 94°C for 30 s, followed by an annealing period of
15 s at 5°C below the T d of the weakest binding primer,
and an extension step at 72°C for 1 to 2 min depending
on the anticipated length of the PCR product.
The nucleotide sequence of cloned PCR and RT-PCR
fragments was determined by using a T7 DNA polymer-
ase sequencing kit and [a-33P]dATP ($2500 Ci/mmol;
mersham Pharmacia Biotech). The plasmid DNA was
enatured by a 10-min treatment with 400 mM NaOH at
oom temperature and precipitated with ethanol prior to
he addition of sequence primer.
onstruction of full-length EAV cDNA clonesDetails about the construction of the full-length EAV
DNA clones pEAV030 and pBRNX1.38 have been pub-
t
mished elsewhere (van Dinten et al., 1997; Glaser et al.,
1999). Although both EAV cDNA clones were derived
from the same virus isolate, they are probably not iden-
tical since plasmid pBRNX1.38 was assembled from
three RT-PCR fragments, while two preexisting cDNA
libraries (de Vries et al., 1990) were used to generate
pEAV030. Furthermore, the EAV coding sequence in
pBRNX1.38 is preceded by a promoter for bacteriophage
SP6 RNA polymerase, whereas a bacteriophage T7 RNA
polymerase promoter directs transcription from plasmid
pEAV030.
Generation of mutant EAV genomes
Recombinant DNA techniques were performed ac-
cording to standard protocols (Ausubel et al., 1987; Sam-
brook et al., 1989) or following the instructions supplied
with specific reagents. Newly constructed plasmids
were propagated in Escherichia coli strain PC2495
Phabagen) after transformation of the bacteria by elec-
roporation using a Gene Pulser II (Bio-Rad) electropo-
ation apparatus and electroporation cuvettes with a
-mm electrode gap (BTX). Mutant EAV-specific DNA
ragments were generated by splicing overlap extension
SOE)–PCR (Horton and Pease, 1991) and purified from
el with the aid of the Qiaquick gel extraction kit (Qia-
en). The overlap between EAV ORFs 5 and 6 was re-
oved by using oligonucleotides 688 (1) and 647 (2) as
he mutagenic primers, oligonucleotides 461 (1) and 434
2) as the outer primers (Table 1), and pBRNX1.38 as the
NA template. The resulting PCR fragment (1225 nt) was
reated with EcoRI and XbaI and the 0.5-kb digestion
roduct was cloned into pBluescript KS(1) 3 EcoRI 3
baI, yielding pAVIs5/6. After nucleotide sequence anal-
sis of the insert, a 0.3-kb EAV-specific fragment carrying
he expected mutations was excised from pAVIs5/6 with
fiI and XbaI and ligated into SfiI- and XbaI-digested
BRNX1.38 to generate pBRNX1.38-5/6 (Fig. 1). The
.5-kb EcoRI–XbaI fragment from pAVIs5/6 was simulta-
eously cloned into EcoRI- and XbaI-digested pEAV030,
ielding pEAV030-5/6 (Fig. 1). For the separation of ORFs
and 5, we used the primer pairs 789 (1) and 788 (2),
87 (1) and 578 (2), and 789 (1) and 578 (2) (Table 1)
ith pEAV030 DNA serving as the template for SOE–
CR. The resulting PCR fragment (894 nt) was ligated
nto pNoTA/T7 using the PRIME PCR CLONER kit (5
rime 3 3 Prime) according to the manufacturer’s in-
tructions. Following nucleic acid sequencing, the re-
ombinant plasmid (pAVIs4/5) was digested with BglII
nd EcoRI, and the EAV-specific 0.8-kb fragment was
urified from gel and inserted into BglII- and EcoRI-
igested pEAV030-BglIIKO to generate pEAV030-BglIIKO-
/5 (Fig. 1). The construct pEAV030-BglIIKO is a deriva-
ive of EAV infectious cDNA clone pEAV030, which has
he BglII site at position 5216 removed by site-directed
utagenesis and contains an additional XbaI site at
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95GENETIC MANIPULATION OF THE EAV GENOMEposition 4761. The vector-containing 3.4-kb KpnI–EcoRI
fragment of pAVIs5/6 was ligated to the 0.9-kb KpnI–
EcoRI fragment of pAVIs4/5, yielding pAVIs456. Next, the
1.3-kb BglII–XbaI fragment from pAVIs456 was inserted
into pEAV030 by a two-step cloning procedure to gener-
ate pEAV030-BglIIKO-456, which has both ORFs 4 and 5
and ORFs 5 and 6 separated by AflII sites (Fig. 1). Finally,
we engineered a full-length cDNA clone in which the EAV
ORF 6 coding sequence was extended immediately
downstream of the start codon with 27 nt encoding
amino acids 2 through 9 of the MHV M protein. For this
purpose, SOE–PCR was performed on pBRNX1.38-5/6
DNA using the primer pair 689 (1) and 793 (2) and
primer pair 792 (1) and 434 (2) (Table 1) to generate the
subfragments and the primer pair A07 (1) and 434 (2) to
amplify their hybridization product. The resulting PCR
product (595 nt) was cloned into pNoTA/T7, yielding pSSI-
M9F. Nucleotide sequence analysis of the insert revealed
that an unintended point mutation (of GAG to AAG) had
been introduced that resulted in a Glu to Lys substitution
at position 9 of the hybrid EAV/MHV M protein (Fig. 1).
The plasmid pSSI-M9F was treated with AflII and XbaI,
and the 0.1-kb digestion product was ligated into pAVIs5/
6 3 AflII 3 XbaI to generate pAVIs5/6-M9F. The latter
onstruct was digested with SfiI and XbaI and the 0.4-kb
ragment was cloned into pBRNX1.38, which had been
igested with the same enzymes, yielding pBRNX1.38-5/
-M9F (Fig. 1).
Construction of expression vectors
The construction of the expression vectors pAVI16,
pSSI-M4A, and pTUG3M-KK has been described else-
where (de Vries et al., 1992; de Haan et al., 1998b). These
plasmids encode the wildtype EAV M protein, an EAV/
MHV M chimera containing the five N-terminal residues
of the MHV M protein followed by amino acids 2 through
162 of the EAV M protein, and a MHV M mutant with a
C-terminal signal for retrieval in the ER, respectively.
RNA transcription
In vitro RNA synthesis was performed according to
Olkkonen et al. (1994) for vectors carrying an SP6 RNA
polymerase promoter and as described by van Dinten et
al. (1997) for plasmids containing a T7 RNA polymerase
promoter. Prior to in vitro transcription, the DNA con-
structs were linearized with XhoI and the reactions were
carried out in the presence of 1 mM G(59)ppp(59)G (Am-
ersham Pharmacia Biotech). After RNA synthesis, the
plasmid DNA in each sample was degraded by treatment
with 1 U of RQ1 RNase-free DNase (Promega) for 30 min
at 37°C. Following heat-inactivation at 65°C for 10 min,
an aliquot of each sample was analyzed by agarose gel
electrophoresis to estimate the amount of genomic EAV
RNA that had been synthesized and the remainder of the
reaction products was transiently stored at 220°C.
aInfection and transfection experiments
BHK-21 cells were transfected with synthetic EAV RNA
by electroporation (Olkkonen et al., 1994). Briefly, 80-cm2
monolayers of newly confluent cells were trypsinized,
resuspended in 10 ml GMEM–10% FBS, and pelleted at
400g for 5 min. The cells were washed in 10 ml phos-
phate-buffered saline (PBS) without CaCl2 and MgCl2,
epelleted, and suspended in 800 ml PBS. One-fifth to
two-fifths of the transcription reaction was then added to
the cell suspension and the mixture was transferred to
electroporation cuvettes with a 4-mm gap size (BTX). The
cells were pulsed twice at 800 V, 25 mF, and with the
pulse controller set at infinite, resuspended in 20 ml
GMEM–10% FBS, and seeded into 185-cm2 flasks. After
incubation for 4 h at 37°C, the cells were transferred to
a CO2 incubator of 39°C to speed up virus replication.
OST-7.1 cells were infected with MVA-T7 and trans-
ected with plasmid DNA using Lipofectin (Gibco BRL
ife Technologies) as detailed before (Snijder et al.,
999). Wherever indicated the cells were incubated in
he presence of 6 mg of brefeldin A per milliliter from 2 h
posttransfection.
BHK-21 cells were either mock-infected or infected at
a high multiplicity of infection with wildtype or mutant
EAV as previously reported (de Vries et al., 1992). The
cells were incubated at 39°C from 2 h after infection.
Metabolic labeling, immunoprecipitation, and
fluorography
OST-7.1 cells infected with MVA-T7 and transfected
with plasmid DNA were labeled for 60 min at 5 h p.i. and
37°C as previously described (de Haan et al., 1998b).
BHK-21 cells infected with EAV and mock-infected
BHK-21 cells were incubated for 30 min in prewarmed
cysteine- and methionine-free medium at the indicated
time points after infection and labeled for 30 min with 160
mCi of Redivue Pro-mix L-[35S]-in vitro cell labeling mix
([35S]Met 1 [35S]Cys; .1000 Ci/mmol; Amersham Phar-
acia Biotech) in 800 ml DMEM without L-cysteine,
L-glutamine, and L-methionine (BioWhittaker) and supple-
ented with 5% dialyzed FBS, 10 mM HEPES (pH 7.4),
nd 2 mM L-alanyl-L-glutamine. After two washes with
omplete medium containing 1 mM L-methionine and 2
mM L-cysteine hydrochloride monohydrate, total lysates
f cells and media were prepared in the presence of
odoacetamide (de Vries et al., 1995b). Alternatively, the
cells were chased for 2 h prior to lysis. In another
experiment, EAV- and mock-infected BHK-21 cells were
continuously labeled for 4 h with 160 mCi [35S]Met 1
35S]Cys per milliliter, the culture medium was cleared by
ow-speed centrifugation and mixed with concentrated
ysis buffer supplemented with iodoacetamide. The pro-
ein extracts were diluted in immunoprecipitation buffer
nd incubated overnight at 4°C with 3 ml of rabbit anti-
peptide serum or 100 ml of mouse hybridoma culture
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96 DE VRIES ET AL.supernatant as described previously (de Vries et al.,
1995b). Immune complexes were collected with formal-
dehyde-fixed and heat-inactivated Staphylococcus au-
reus cells (PANSORBIN cells; Calbiochem) and analyzed
in SDS–15 to 17.5% polyacrylamide gels using estab-
lished procedures (Snijder et al., 1999). After electro-
phoresis the gels were processed for fluorography as
previously reported (Snijder et al., 1999).
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